2019
Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity
Krause P, Kavathas P, Ruddle N. Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity. 2019, 265-276. DOI: 10.1007/978-3-030-25553-4_16.ChaptersSubset of patientsMonoclonal antibodiesSide effectsAutoimmune side effectsRespiratory syncytial virusMinimal side effectsInitial unresponsivenessCheckpoint inhibitorsAdverse eventsField of immunologyCheckpoint inhibitionTreatment failureCytokine inhibitorsSyncytial virusAutoimmune diseasesCancer immunotherapyInhibitory receptorsLate toleranceLung cancerImmune cellsPassive transferImmune regulationImmune responseImmunotherapyLatent infection
1992
Characterization of a direct effect of phorbol myristate acetate on human neutrophil cell membrane using 31D8 monoclonal antibody
Woronick C, Maderazo E, Anthony M, Krause P, Sha'afi R. Characterization of a direct effect of phorbol myristate acetate on human neutrophil cell membrane using 31D8 monoclonal antibody. Journal Of Leukocyte Biology 1992, 51: 289-295. PMID: 1541911, DOI: 10.1002/jlb.51.3.289.Peer-Reviewed Original ResearchConceptsPolymorphonuclear neutrophilsAntigen expressionLate effectsAlpha-tocopherolProtein kinase CInhibitor of cyclooxygenaseNormal polymorphonuclear neutrophilsKinase CPhorbol myristate acetateNeutrophil cell membraneProtective effectConcentrations of PMADirect effectHuman neutrophilsMonoclonal antibodiesMyristate acetateInhibitory affectRapid initiationMembrane stabilizationBetamethasoneNeutrophilsOxidative burstInactive analoguePMAPMA effect
1986
Polymorphonuclear Leukocyte Heterogeneity in Neonates and Adults
Krause P, Malech H, Kristie J, Kosciol C, Herson V, Eisenfeld L, Pastuszak W, Kraus A, Seligmann B. Polymorphonuclear Leukocyte Heterogeneity in Neonates and Adults. Blood 1986, 68: 200-204. DOI: 10.1182/blood.v68.1.200.200.Peer-Reviewed Original Research